Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.
Shares of Quest Diagnostics Inc. DGX slid 1.10% to $178.28 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.23% to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback